OMLYCLO (omalizumab-igec)
OMLYCLO is indicated for the treatment of Asthma; Chronic Rhinosinusitis; Nasal Polyps; Food Allergy; Anaphylaxis; Chronic Spontaneous Urticaria.
How OMLYCLO Works
Omalizumab-igec binds to IgE, which inhibits the antibody from binding to the high-affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and dendritic cells. This process results in the down-regulation of these receptors and, in allergic asthma, inhibits IgE-mediated inflammation by reducing blood and tissue eosinophils and inflammatory mediators. In patients with chronic spontaneous urticaria, the drug lowers free IgE levels and down-regulates IgE receptors, though the exact mechanism for symptom improvement in this specific condition is unknown.
Details
- Status
- Prescription
- First Approved
- 2025-03-07
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
OMLYCLO Approval History
What OMLYCLO Treats
6 indicationsOMLYCLO is approved for 6 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Asthma
- Chronic Rhinosinusitis
- Nasal Polyps
- Food Allergy
- Anaphylaxis
- Chronic Spontaneous Urticaria
OMLYCLO Boxed Warning
ANAPHYLAXIS Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab products. Anaphylaxis has occurred as early as after the first dose of omalizumab products, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate Omalizumab-igec therapy in a healthcare setting and closely observe patients for an app...
WARNING: ANAPHYLAXIS Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab products. Anaphylaxis has occurred as early as after the first dose of omalizumab products, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate Omalizumab-igec therapy in a healthcare setting and closely observe patients for an appropriate period of time after Omalizumab-igec administration. Health care providers administering Omalizumab-igec should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of Omalizumab-igec should be based on criteria to mitigate risk from anaphylaxis [see Dosage and Administration (2.6) , Warnings and Precautions (5.1) and Adverse Reactions (6.1 , 6.2) ] . WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning. Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab products. Anaphylaxis has occurred after the first dose of omalizumab products but also has occurred beyond 1 year after beginning treatment. Initiate Omalizumab-igec therapy in a healthcare setting, closely observe patients for an appropriate period of time after Omalizumab-igec administration and be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Selection of patients for self-administration of Omalizumab-igec should be based on criteria to mitigate risk from anaphylaxis. ( 2.6 , 5.1 , 6.1 , 6.2 )
OMLYCLO Target & Pathway
ProTarget
A cytokine that promotes Th2 immune responses and IgE production. IL-4 drives allergic inflammation in atopic dermatitis and asthma. Blocking IL-4 (often together with IL-13) reduces the type 2 inflammation underlying these conditions.
Pharmacists can substitute OMLYCLO for Xolair without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
OMLYCLO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to OMLYCLO
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OMLYCLO FDA Label Details
Indications & Usage
FDA Label (PDF)OMLYCLO is indicated for the treatment of Asthma; Chronic Rhinosinusitis; Nasal Polyps; Food Allergy; Anaphylaxis; Chronic Spontaneous Urticaria.
WARNING: ANAPHYLAXIS Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab products. Anaphylaxis has occurred as early as after the first dose of omalizumab products, but also ...
Track OMLYCLO with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.